Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALIOF stock logo
ALIOF
ALIOF
$278.50
$278.50
$138.01
$286.30
$29.89BN/A924 shsN/A
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$9.82
+3.3%
$9.59
$8.37
$13.14
N/A0.23199,191 shs1.14 million shs
BeiGene, Ltd. stock logo
BGNE
BeiGene
$194.32
$146.21
$248.16
$18.03B0.57336,748 shs331,608 shs
Olympus Co. stock logo
OCPNY
Olympus
$18.00
-1.4%
$18.00
$16.80
$74.99
$23.15B0.7860,265 shs400 shs
Terumo Corp. stock logo
TRUMY
Terumo
$16.52
-0.6%
$18.24
$14.06
$21.22
$24.46B0.79158,750 shs156,187 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALIOF stock logo
ALIOF
ALIOF
0.00%0.00%0.00%0.00%0.00%
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.00%-0.94%-1.25%+4.16%-9.08%
BeiGene, Ltd. stock logo
BGNE
BeiGene
0.00%0.00%0.00%0.00%+21.38%
Olympus Co. stock logo
OCPNY
Olympus
0.00%0.00%0.00%0.00%0.00%
Terumo Corp. stock logo
TRUMY
Terumo
0.00%-2.52%-7.77%-11.92%-4.48%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ALIOF stock logo
ALIOF
ALIOF
N/AN/AN/AN/AN/AN/AN/AN/A
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
1.4909 of 5 stars
3.50.00.00.00.60.80.6
Olympus Co. stock logo
OCPNY
Olympus
N/AN/AN/AN/AN/AN/AN/AN/A
Terumo Corp. stock logo
TRUMY
Terumo
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALIOF stock logo
ALIOF
ALIOF
0.00
N/AN/AN/A
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.00
N/AN/AN/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
3.00
Buy$274.20∞ Upside
Olympus Co. stock logo
OCPNY
Olympus
0.00
N/AN/AN/A
Terumo Corp. stock logo
TRUMY
Terumo
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALIOF stock logo
ALIOF
ALIOF
N/AN/AN/AN/AN/AN/A
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$12.56BN/A$1.86 per share5.29$5.52 per shareN/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
$3.32B0.00N/AN/A$37.10 per share0.00
Olympus Co. stock logo
OCPNY
Olympus
$7.74B2.99$1.22 per share14.76$3.50 per share5.14
Terumo Corp. stock logo
TRUMY
Terumo
$6.80B3.59$0.89 per share18.47$6.10 per share2.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALIOF stock logo
ALIOF
ALIOF
N/AN/A0.00N/AN/AN/AN/AN/A
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$334.93M$0.1757.7714.44N/A2.65%16.55%7.35%7/29/2025 (Estimated)
BeiGene, Ltd. stock logo
BGNE
BeiGene
-$881.71M-$8.24N/AN/AN/A-25.94%-25.12%-14.95%N/A
Olympus Co. stock logo
OCPNY
Olympus
$1.03B$0.8221.9520.691.0713.80%24.30%9.30%N/A
Terumo Corp. stock logo
TRUMY
Terumo
$772.05M$0.5231.77N/A11.28%8.48%6.37%8/6/2025 (Estimated)

Latest OCPNY, ALIOF, ALPMY, BGNE, and TRUMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q4 2025
Terumo Corp. stock logo
TRUMY
Terumo
$0.1454$0.08-$0.0654$0.08$1.79 billion$1.79 billion
4/25/2025Q4 2025
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.1474$0.27+$0.1226$0.27$3.02 billion$3.22 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ALIOF stock logo
ALIOF
ALIOF
N/AN/AN/AN/AN/A
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.353.56%N/A205.88%N/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
N/AN/AN/AN/AN/A
Olympus Co. stock logo
OCPNY
Olympus
$0.080.44%N/A9.76%N/A
Terumo Corp. stock logo
TRUMY
Terumo
$0.181.09%N/A34.62%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALIOF stock logo
ALIOF
ALIOF
N/AN/AN/A
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.37
1.13
0.85
BeiGene, Ltd. stock logo
BGNE
BeiGene
0.05
1.93
1.72
Olympus Co. stock logo
OCPNY
Olympus
0.59
1.99
1.48
Terumo Corp. stock logo
TRUMY
Terumo
0.12
3.00
1.78

Institutional Ownership

CompanyInstitutional Ownership
ALIOF stock logo
ALIOF
ALIOF
N/A
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
48.55%
Olympus Co. stock logo
OCPNY
Olympus
0.03%
Terumo Corp. stock logo
TRUMY
Terumo
N/A

Insider Ownership

CompanyInsider Ownership
ALIOF stock logo
ALIOF
ALIOF
N/A
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
7.43%
Olympus Co. stock logo
OCPNY
Olympus
N/A
Terumo Corp. stock logo
TRUMY
Terumo
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ALIOF stock logo
ALIOF
ALIOF
N/A107.33 millionN/ANot Optionable
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
14,754N/AN/ANot Optionable
BeiGene, Ltd. stock logo
BGNE
BeiGene
9,00097.62 million90.20 millionOptionable
Olympus Co. stock logo
OCPNY
Olympus
31,5571.29 billionN/ANot Optionable
Terumo Corp. stock logo
TRUMY
Terumo
30,0001.48 billionN/ANot Optionable

Recent News About These Companies

Terumo (OTCMKTS:TRUMY) Shares Gap Up - Here's Why
Terumo Corp ADR TRUMY
Terumo Corporation (TRUMF) Q3 2025 Earnings Call Transcript
Terumo Corporation (TRUMY)
Terumo (OTC: TRUMY)

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALIOF stock logo

ALIOF OTCMKTS:ALIOF

$278.50 0.00 (0.00%)
As of 09/27/2022

Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland.

Astellas Pharma stock logo

Astellas Pharma OTCMKTS:ALPMY

$9.82 +0.31 (+3.26%)
As of 03:58 PM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

BeiGene stock logo

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Olympus stock logo

Olympus OTCMKTS:OCPNY

$18.00 -0.25 (-1.37%)
As of 01/31/2023

Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.

Terumo stock logo

Terumo OTCMKTS:TRUMY

$16.52 -0.10 (-0.60%)
As of 03:59 PM Eastern

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.